Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
ShangPharma
ShangPharma
Activities:
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Fasenra for EGPA: addressing unmet needs
Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities
Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Design & Build
ShangPharma and Qidong Biopharma sign US$60m investment deal in China
Preclinical research facility and a state-of-the-art biologics manufacturing facility to be built in Qidong
Manufacturing
Mitchell Reff becomes Chief Biologics Officer at ShangPharma
He brings more than 30 years of reaearch experience to the position
Manufacturing
ShangPharma appoints Arthur Taveras as President and CSO
Taveras brings the experience of a 24-year career to the Chinese contract research organisation
Buyouts prove popular in China
Chinese pharma companies turning to private capital
You need to be a subscriber to read this article.
Click here
to find out more.
Finance
Picking up a good deal
This month Asia correspondent A Nair looks at why the emerging economies provide so many tempting takeover targets for Big Pharma
Research & Development
ShangPharma opens new plant to support Eli Lilly
Also signs a multi-year extension of its contract with the US firm
Subscribe now